News

The funding has been awarded by its existing investors along with Forbion Capital Partners, Credit Agricole Private Equity and Vesalius BioCapital. The company has progressed its lead candidate,

NOX-H94 is a Spiegelmer that targets peptide hormone hepcidin, the key regulator of iron metabolism. The trial aims to investigate the tolerability and safety of NOX-H94 with an

The results of the trial demonstrated that Resminostat monotherapy showed substantial anti-tumour activity, including complete and partial tumour responses. Furthermore, the study demonstrated that the drug was safe

The acquisition allows IntrinsiQ to become a part of ION Solutions, a unit of AmerisourceBergen Specialty Group. The combination of IntrinsiQ’s software applications and ION Solutions’ oncology technology

Additionally, the US Patent and Trademark Office (USPTO) has issued a notice of allowance (NoA) to AMT for its patent application entitled ‘AAV vectors produced in insect cells,’

Selbelle brand lineup comprises range of OTC products to relieve weakness of the stomach associated with aging or other factors. New Selbelle which is a combination of lipase

As per the terms of the deal, Evotech is eligible to pay a sum of $10m as an upfront payment from Roche. Additionally, Evotec is eligible to get

The protein free media improves safety and stability in cultivation of cell-lines for manufacturing viral-based vaccines. The agreement is in line with exploring the extended patent application filed

JAK2 inhibitor, is Lilly’s early stage investigational proprietarycompound, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms. The new